Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.45 |
| ▸ | HTR3B | O95264 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.45 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.45 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.34 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16097832 | 0.85 | HTR3E (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16098630 | 0.84 | HTR3E (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16103357 | 0.84 | HTR3E (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16103531 | 0.82 | HTR3E (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16103633 | 0.81 | HTR3E (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16102965 | 0.80 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL16097868 | 0.79 | HTR3E (0.43) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16098023 | 0.75 | HTR3A (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16097776 | 0.75 | HTR3E (0.39) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL16103152 | 0.73 | HTR3E (0.40) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790211-B2 | 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-17 | — | — | US | claimed |
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-09-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280694-A1 | 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | HTR3E 18/4885HTR3B 6/4885HTR3A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.